Literature DB >> 2654018

Empiric treatment of infection during granulocytopenia: a comprehensive approach.

J Klastersky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2654018     DOI： 10.1007/bf01646877

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  29 in total

1.  Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.

Authors:  J D Meyers; E C Reed; D H Shepp; M Thornquist; P S Dandliker; C A Vicary; N Flournoy; L E Kirk; J H Kersey; E D Thomas
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

2.  Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

Authors:  J P Sculier; J Klastersky
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

3.  Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group.

Authors:  S C Schimpff; H Gaya; J Klastersky; M H Tattersall; S H Zinner
Journal:  J Infect Dis       Date:  1978-01       Impact factor: 5.226

4.  Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients?

Authors:  J H Joshi; S C Schimpff; J H Tenney; K A Newman; C A de Jongh
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

Review 5.  Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside.

Authors:  P DeJace; J Klastersky
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

6.  Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer.

Authors: 
Journal:  J Clin Oncol       Date:  1983-10       Impact factor: 44.544

7.  Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae.

Authors:  Y Van Laethem; H Lagast; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

8.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

Authors:  Thierry Calandra; J Klastersky; H Gaya; M P Glauser; F Meunier; S H Zinner
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

9.  A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients.

Authors:  V Fainstein; G P Bodey; L Elting; R Bolivar; M J Keating; K B McCredie; M Valdivieso
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

10.  Prospective randomized trial of antibiotic prophylaxis in acute leukemia.

Authors:  G P Bodey; M J Keating; K B McCredie; L Elting; B Rosenbaum; E J Freireich
Journal:  Am J Med       Date:  1985-03       Impact factor: 4.965
View more
  6 in total

1.  Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.

Authors:  M L van Ogtrop; H F Guiot; H Mattie; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.

Authors:  E Ulrich; M Trautmann; B Krause; A Bauernfeind; H Hahn
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

Review 3.  Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.

Authors:  F de Lalla
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

4.  Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo.

Authors:  M L van Ogtrop; H Mattie; H F Guiot; E van Strijen; A M Hazekamp-van Dokkum; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

5.  Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.

Authors:  O Ozyilkan; U Yalçintaş; S Başkan
Journal:  Korean J Intern Med       Date:  1999-07       Impact factor: 2.884

6.  Comparing the efficacy of ceftazidime and meropenem in treatment of febrile neutropenia in pediatric patients with cancer.

Authors:  F Ferdosian; R Ghiliyan; A Hashemi; B Akhondzadeh; E Gholampoor
Journal:  Iran J Ped Hematol Oncol       Date:  2013-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.